Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita

© 2024 BioAdvance. All Rights Reserved. | Privacy Policy | Site by Loudmark
101 West Elm Street, Suite 330, Conshohocken, PA 19428 | (610) 230-0544